Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden

We retrospectively investigated the pharmacokinetics and exposure‐efficacy/safety relationships of single‐agent atezolizumab based on tissue tumor mutational burden (tTMB) status (high vs low [≥16 vs <16 mutations/megabase]) in a pan‐tumor population from seven clinical trials. Data sources inclu...

Descripción completa

Detalles Bibliográficos
Autores principales: Shemesh, Colby S., Chan, Phyllis, Legrand, Fatema A., Shames, David S., Das Thakur, Meghna, Shi, Jane, Bailey, Lorna, Vadhavkar, Shweta, He, Xian, Zhang, Wei, Bruno, René
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689240/
https://www.ncbi.nlm.nih.gov/pubmed/33241650
http://dx.doi.org/10.1002/prp2.685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689240/
https://www.ncbi.nlm.nih.gov/pubmed/33241650
http://dx.doi.org/10.1002/prp2.685

Ejemplares similares